<DOC>
	<DOCNO>NCT00805935</DOCNO>
	<brief_summary>This multicenter , randomize , open-label exploratory study perform approximately 200 polycystic ovary syndrome ( PCOS ) otherwise healthy female undergo vitro fertilization ( IVF ) . Each study center follow standard practice vitro fertilization ( IVF ) within study parameter note protocol . The study center use market product purchase Schraft 's Pharmacy phase study ( down-regulation , stimulation , ovulation induction , luteal support ) . Subjects randomly assign highly purify menotropin ( Menopur® ) follitropin beta ( Follistim Pen® ) stimulation progesterone vaginal insert ( Endometrin® ) progesterone oil luteal support . Subjects return study center regular schedule clinic visit require per vitro fertilization ( IVF ) protocol site specify time cycle ( Stimulation Day 6 , Day human chorionic gonadotropin ( hCG ) , first serum pregnancy test ) estradiol ( E2 ) , progesterone ( P4 ) human chorionic gonadotropin ( hCG ) lab . All subject require complete final study visit completion luteal support negative serum pregnancy test follow embryo transfer .</brief_summary>
	<brief_title>Menopur® Versus Follistim® Polycystic Ovarian Syndrome ( PCOS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Menotropins</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>1 . Premenopausal females age 18 42 year 2 . Diagnosed polycystic ovary syndrome ( PCOS ) , use criterion adopt 2003 Rotterdam PCOS Consensus ( 2 3 , exclude etiology [ congenital adrenal hyperplasia , androgensecreting tumor , Cushing 's syndrome ] ) Oligo anovulation Clinical and/or biochemical sign hyperandrogenism Polycystic ovaries 3 . Body mass index ( BMI ) 1839 4 . Early follicular phase ( Day 3 ) follicle stimulate hormone ( FSH ) &lt; 15 IU/L estradiol ( E2 ) within normal limit 5 . Documented history infertility ( e.g. , unable conceive least one year , 6 month woman &gt; 38 year age , bilateral tubal occlusion absence , male factor exclude severe male factor require invasive surgical sperm retrieval . Donor sperm may use . ) 6 . Transvaginal ultrasound screen consistent finding adequate assist reproductive technology ( ART ) respect uterus adnexa 7 . Signed informed consent 1 . Gestational surrogate carrier , donor oocyte 2 . Presence clinically relevant systemic disease ( e.g. , uncontrolled thyroid adrenal dysfunction , organic intracranial lesion pituitary tumor , insulindependent diabetes mellitus , uterine cancer ) 3 . Surgical medical condition , judgment Investigator Sponsor , may interfere absorption , distribution , metabolism , excretion drug use 4 . Two previous fail vitro fertilization ( IVF ) cycle vitro fertilization ( IVF ) /assisted reproductive technology ( ART ) failure due poor response gonadotropin , define development 2 mature follicle 5 . History recurrent pregnancy loss , define two clinical loss 6 . Presence abnormal uterine bleeding undetermined origin 7 . Current recent substance abuse , include alcohol smoking &gt; 10 cigarette per day 8 . Refusal inability comply requirement Protocol reason , include schedule clinic visit laboratory test 9 . Participation experimental drug study within 30 day prior Screening 10 . Severe male factor require invasive surgical sperm retrieval ( e.g. , microsurgical epididymal sperm aspiration [ MESA ] , testicular sperm extraction [ TESE ] ) 11 . Prior hypersensitivity protocol drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>pre-menopausal woman</keyword>
	<keyword>PCOS</keyword>
	<keyword>polycystic ovarian syndrome</keyword>
	<keyword>infertility</keyword>
	<keyword>IVF</keyword>
	<keyword>vitro fertilization</keyword>
</DOC>